GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Float Percentage Of Total Shares Outstanding

Mesoblast (Mesoblast) Float Percentage Of Total Shares Outstanding : 93.80% (As of May. 22, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Mesoblast Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Mesoblast's float shares is 1,070.51 Mil. Mesoblast's total shares outstanding is 1,141.24 Mil. Mesoblast's float percentage of total shares outstanding is 93.80%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Mesoblast's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Mesoblast's Institutional Ownership is 8.56%.

Mesoblast Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Mesoblast's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=1,070.51/1,141.24
=93.80%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast (Mesoblast) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mesoblast Ltd (OTCPK:MEOBF) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
ASX:CU6 ASX:CUV ASX:IMU ASX:IMM ASX:OPT ASX:PYC ASX:BOT ASX:RAC ASX:DXB ASX:PIQ OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
MESO:USA LWB:Germany MSB:Australia
Address
Level 38, 55 Collins Street, Melbourne, VIC, AUS, 3000
Website
https://www.mesoblast.com
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.